Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-PD-1 blockade plus radiotherapy in previously untreated metastatic melanoma
KCT0004145Phase 2Not yet recruiting
- Sponsor
- Yonsei University Health System
- Start
- Jul 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab, pembrolizumab in melanoma, sponsored by Yonsei University Health System. Planned start Jul 2019; status: not yet recruiting.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on KCT0004145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0004145.